In a combined meeting with two advisory committees, the FDA will be spending today and tomorrow assessing the associated health risks, determining who is being prescribed such medication, and considering an application for a new oral Low T medication, as opposed to current drugs which are administered as gels, injections or implants.
To read more, please visit our Low-T blog!
Call or text 877-751-9800 or complete a Free Case Evaluation form